VRC-HIVADV038-00-VP

Drug Profile

VRC-HIVADV038-00-VP

Alternative Names: HIV vaccine rAd5-Env-A VRC; rAd5 HIV vaccine VRC Env-A; rAd5-EnvA vaccine; VRC-rAd5 HIV vaccine Env-A

Latest Information Update: 29 Jun 2017

Price : $50

At a glance

  • Originator GenVec; National Institute of Allergy and Infectious Diseases
  • Developer National Institute of Allergy and Infectious Diseases
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported HIV-1 infections

Most Recent Events

  • 16 Jun 2017 GenVec has been acquired by Intrexon Corporation
  • 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-1-infections(Prevention, In volunteers) in USA (IM, Injection)
  • 01 May 2014 National Institute of Allergy and Infectious Diseases completes a phase I trial in HIV-1 infection (prevention, in volunteers) in USA (NCT00479999)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top